Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epacadostat and IP NK Cells for Recurrent Ovarian Cancer
NCT02118285Phase 1Completed
- Sponsor
- Masonic Cancer Center
- Start
- Jul 2014
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of epacadostat in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Masonic Cancer Center. Primary endpoint: Maximum Tolerated Dose of INCB024360 at 90 days. Started Jul 2014; status: completed.
02
Drugs
epacadostat
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT02118285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02118285.